An observational study in Maternal-Fetal Exchange, sponsored by Romanian Society of Anesthesia and Intensive Care. Completed at 1 site in Romania. Open to participants aged 1 Day to 28 Days. Per ClinicalTrials.gov, last updated 2017-08-29.
Sponsored by Romanian Society of Anesthesia and Intensive Care · Observational
Maternal high blood pressure remodels the intrauterine environment of the fetus by altering hormonal and cellular signaling patterns and, as a result increases the risk of fetal and neonatal mortality and morbidity. Newborns of these mothers have an increased risk of intrauterine growth restriction, premature birth and hematological abnormalities, such as thrombocytopenia, polycythemia, and neutropenia. The purpose of the article is to review neonatal thrombocytopenia and neutropenia as a consequence of maternal high blood pressure and to establish the optimal management of these cases.
Pregnancy induced hypertension (PIH) and preeclampsia (preE) are caused by gestation and have an onset after 20 weeks of pregnancy. Although the exact etiology of PIH and preE remains unknown, two interconnected mechanisms have been identified to play an important role in the pathogenesis: dysfunction of the placental trophoblast and endothelial dysfunction within the maternal systemic vasculature. The endothelium has been identified as the target tissue of the disease. Endothelial alterations ultimately manifest as placental hypoxia and hypoplasia. The neonatal thrombocytopenia and neutropenia after pregnancy-induced hypertension is a result of inhibition of fetal bone marrow production of the myeloid lineage due to intrauterine hypoxic environment. This study aims to investigate the hematological profile in term and preterm infants born to mothers with preeclampsia. The current retrospective observational study was conducted at the Clinic of Obstetrics, Gynecology and Neonatology of the Emergency County Hospital, Timisoara over a period of three years, from January 2014 to December 2016. All inborn patient files were analyzed as anonymised limited data sets from archived records of the Neonatology Department.
All newborns admitted to the Neonatology Department who met the Inclusion Criteria.
Exclusion Criteria:
AGA Control Group Appropriate for gestational age newborns of healthy mothers
Other: AGA - Control group
SGA - Control Group Small for gestational age newborns of healthy mothers
Other: SGA - Control group
AGA-PIH Study Group Appropriate for gestational age newborns of mothers with pregnancy induced hypertension
Other: AGA-PIH Study group
SGA-PIH Study Group Small for gestational age newborns of mothers with pregnancy induced hypertension
Other: SGA-PIH Study group
Data processing from Patient Medical Files
Data processing from Patient Medical Files
Monitoring PIH-related changes in the newborn
Monitoring PIH-related changes in the newborn
Hematological Changes in the Newborns of Mothers with Pregnancy Induced Hypertension
Evaluating the impact of Maternal Pregnancy Induced Hypertension on fetal and neonatal hematopoiesis with focus on the myeloid lineage.
Time frame: Blood profiles of newborns aged between 1-28 days were evaluated.
Plan to share: No
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Romanian Society of Anesthesia and Intensive Care